iBio, Inc.
IBIOHealthcare|Biotechnology|US
$0.74
+0.01 (+1.16%)
DCF Value
$0.49
Tangible Book / Share
$0.81
Cash / Share
$0.85
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07487376 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults | Overweight , Obesity | P1 | Recruiting | 32 | RCT, Double-blind | IBIO-600, Placebo |
| NCT07890870 A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. | Obesity & Overweight | P1 | Not Yet Recruiting | 32 | RCT, Double-blind | IBIO-610, Placebo |
| NCT04842370 Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML | Relapsed or Refractory Acute Myeloid Leukemia | P1 | Unknown | 42 | Open-label | PHI-101 |
| NCT04678102 Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma | P1 | Unknown | 36 | Open-label | PHI-101 administration |